Storax Inhibits Caveolae-Mediated Transcytosis at Blood-Brain Barrier After Ischemic Stroke in Rats

Abstract

Background and Purpose: Blood-brain barrier (BBB) disruption following ischemic stroke (IS) contributes to hemorrhagic transformation, brain edema, increased neural dysfunction, secondary injury, and mortality. The prevailing view attributes the destruction of tight junction proteins (TJs) to the resulting BBB damage following IS. However, recent studies define a stepwise impairment of the transcellular barrier followed by the paracellular barrier which accounts for the BBB leakage in IS. The increased endothelial transcytosis that has been proven to be caveolae-mediated, preceding and independent of TJs disintegration. Emerging experimental investigations suggested Storax attenuates BBB damage after stroke. This study aimed to test our hypothesis that Storax inhibits caveolae-mediated transcytosis at BBB after ischemic stroke in rats.Methods: Male Wistar rats (250–300 g) were subjected to transient middle cerebral artery occlusion (t-MCAO). Brain water content and the cerebral infarction size were assessed by brain tissue drying-wet method and 2,3,5-triphenyltetrazolium chloride (TTC) staining. BBB permeability was detected by the leakage of Evans blue and Albumin-Alexa594. The ultrastructure of BBB was examined by transmission electron microscopy (TEM). Cav-1 and Mfsd2a were quantified by western blotting and immunofluorescence staining, AQP4, PDGFR-β, ZO-1 and Occludin were quantified by western blotting.Results: Storax treatment of 0.1 g/kg had no significant effects on brain lesions. Storax treatment of 0.2, 0.4, and 0.8 g/kg led to a significant decrease in infarction size, and the Storax 0.4, 0.8 g/kg groups displayed a significant reduction in brain water content. Storax treatment of 0.8 g/kg showed mild toxic reactions. Thus, 0.4 g/kg Storax was selected as the optimal dose for subsequent studies. Storax significantly inhibited the fluorescent albumin intensity in the brain parenchyma and the number of caveolae in ECs, alongside attenuating the ultrastructural disruption of BBB at 6 h after stroke. Meanwhile, Storax significantly increased the expression of Mfsd2a and PDGFR-β, and decrease the expression of Cav-1 and AQP4, corresponding to the significantly decreased Cav-1 positive cells and increased Mfsd2a positive cells. However, Storax has no significant effects on Evan blue leakage or the expression ZO-1, Occludin.Conclusion: Our experimental findings demonstrate Storax treatment inhibits caveolae-mediated transcytosis at BBB in the focal stroke model of rats. We also speculate that regulation of Cav-1, Mfsd2a, AQP4, and PDGFR-β expressions might be associated with its beneficial pharmacological effect, but remain to define and elucidate in future investigation.

The Expression of Major Facilitator Superfamily Domain-Containing Protein2a (Mfsd2a) and Aquaporin 4 Is Altered in the Retinas of a 5xFAD Mouse Model of Alzheimer’s Disease

“…It has been postulated that Mfsd2a may serve to modulate transcytotic mechanisms in CNS endothelial cells for therapeutic purposes [ 66 ]. Recent research confirmed that storax attenuated BBB disruption by upregulating Mfsd2a and inhibiting Cav-1 in the endothelial cells in order to arrest the progression of cerebral ischemia [ 67 ]. Similarly, treatment with LPC-DHA, transported through Mfsd2a, strongly improved retinal function in 5xFAD mice [ 68 ], and treatment with fish oil significantly increased Mfsd2a expression and blood vessel coverage in the retinas of wild-type mice [ 69 ].…”

Complementary therapy with Chinese aromatic herbs to promote awakening in a comatose patient: A case report

“…[33,38] Styrax treatment inhibits caveolaemediated transcytosis at BBB in the focal stroke model of rats. [39] Besides modulating BBB permeability, other mechanisms include modulating inflammatory responses, regulating central excitatory and inhibitory neurons and neurotransmitters, [40,41] improving local microcirculation, and enhancing cerebral metabolism. [42]…”

Protective effect and mechanism of styrax on ischemic stroke rats: metabonomic insights by UPLC-Q/TOF-MS analysis

“…Furthermore, styrax treatment after focal ischemic stroke improves long-term neurological outcomes, reduces cerebral infarct volume, and inhibits caveolae-mediated transcytosis in the blood-brain barrier (Zhou et al. 2021 , 2022 ). However, the exact mechanisms underlying the cerebral protective effects of styrax at the metabolite level are yet to be elucidated.…”